… oxaliplatin (CAPOX) is a standard treatment for resected colon cancer; however, in patients
with moderate renal impairment, … National Cancer Institute Organ Dysfunction Working Group …

… For the elderly, there is a need to provide the best cancer treatment possible, whether … of
cancer treatment that may be exacerbated by poor renal function or general functional status. …

… Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with
impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group …

… the Cancer and Leukemia Group B (CALGB) Pharmacology and … multiorgan health rather
than strictly liver function. The NCI … and the NCI Organ Dysfunction Working Group employs the …

… study showed that reducing the dose of oxaliplatin is unnecessary in patients with impaired
hepatic function, … pharmacokinetics of oxaliplatin were independent of the degree of hepatic …

… (9) compared free platinum AUC and toxicity of oxaliplatin among groups of patients with
different levels of renal impairment and found that the severity of renal impairment was …

… Safety and anti-tumor efficacy in patients with impaired hepatic function were also explored.
… of the present study are representative for cancer patients with hepatic impairment combined …

… This was an open-label, non-randomized, dose-escalating, … in patients with impaired hepatic
function: study design, data … NCI organ dysfunction working group (NCI-ODWG) criteria for …

… of hepatic arterial infusion of oxaliplatin are feasible in patients … for treating hepatic metastases
from colon cancer in patients … use of oxaliplatin in patients with mild renal impairment has …